

Appl. No. : 10/632,531
Filed : August 1, 2003

REMARKS

The Examiner for the instant application contacted Applicants' representative by telephone and indicated that a Restriction Requirement was being imposed with respect to the instant application. Three groups were identified: Group I, consisting of Claims 15-25, directed to compounds; Group II, consisting of Claims 1-14, directed to methods of synthesis; and Group III, consisting of Claims 26-40, directed to pharmaceutical compositions and methods of treatment and/or prevention. Applicants elected Group I, Claims 15-25, directed to compounds.

In view of the Applicants election of Group I consisting of Claims 15-25, Claims 1-14 and 26-40 are cancelled without prejudice to pursuing the claims in a divisional, continuation, or continuation-in-part application. Also, Claim 15 has been amended to clarify the claim and correct inadvertent errors. The R_5 substituent has been removed from Formula I in view of the fact that the definition for Y in the claim recited "N substituted with R_5 ," "an oxygen atom," and "a sulfur atom," which groups cannot form stable compounds when substituted with the R_5 originally recited in Formula I. The definition for Y in the claim has also been amended to remove reference to "a nitrogen atom" and to specify that the methylene group is substituted with one or more R_5 groups. The Applicants respectfully submit that those of skill in the art would recognize that these amendments merely clarify what was originally intended by the claim, namely, that the Y group recited in Formula I can be a substituted nitrogen; an unsubstituted oxygen, sulfur, or oxidized sulfur; and an optionally substituted methylene group. Accordingly, no new matter is being introduced.

Additionally, the proviso in Claim 15 has been amended to correct inadvertent errors. Specifically, " R_6 " has been replaced with " R_4 " and "3,3-dimethylbutyl-1-ene" has been replaced with "3,3-dimethylpropyl-1-ene." The Applicants submit that it is clear from the instant specification that one purpose of the proviso is to exclude the dehydrophenylahistin compound recited, for example, in paragraph 7. This compound contains a 3,3-dimethylpropyl-1-ene substituent in the R_4 position and not a 3,3-dimethylpropyl-1-ene in the R_6 position. Accordingly, no new matter is being introduced by this amendment.

Appl. No. : 10/632,531
Filed : August 1, 2003

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: August 26, 2005

By:



Marc T. Morley
Registration No. 52,051
Attorney of Record
Customer No. 20,995
(619) 235-8550

1892830:ad2:082605